Both the National Comprehensive Cancer Network (2005) and The Cancer Care Ontario Practice Guidelines Initiative (Breast Cancer Disease Site Group, 2002) have added aromatase inhibitors to their guidelines alongside tamoxifen as first-line therapy in postmenopausal oestrogen receptor-positive women with advanced breast cancer. The gene discussed is CYP19A1; the disease is breast cancer.